FEMASYS INC
No SEC Form 4 filings for $FEMY in the last 30 days.
See all $FEMY insider activity →Femasys Inc. (FEMY) announced that Minnesota Women's Care will use its FemVue fertility diagnostic and FemaSeed Complete treatment across all four locations. The adoption follows Femasys' August financing, aimed at expanding its commercial team and OB/GYN adoption. The company's stock closed at $2.67 on Monday, up to $2.81 in pre-market trading.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Femasys (FEMY) announced FDA approval of its modular PMA pathway for FemBloc, a non-surgical permanent birth control. The approach allows early review of key components. FemBloc is in the FINALE trial for U.S. approval. FEMY stock rose 35.45% in premarket trading.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FEMY (FEMASYS INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent FEMY coverage spans insider activity, regulation and technology.
Adoption could boost sales of fertility products and support near‑term revenue growth.
Strategic partnership expands distribution, modestly positive for FEMY.
Positive regulatory milestone likely to boost stock momentum.
Capital raise and regulatory/commercial milestones reduce near-term financing risk and support commercialization, but losses and low cash remain key overhangs.
A small, non-10b5-1 insider open-market buy provides mild sentiment support but is unlikely to change fundamentals on its own.
AlphAI scores every news story that mentions FEMY with an AI model for sentiment and relevance, and aggregates insider trades from FEMASYS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Femasys Inc. (FEMY) announced that Minnesota Women's Care will use its FemVue fertility diagnostic and FemaSeed Complete treatment across all four locations. The adoption follows Femasys' August financing, aimed at expanding its commercial team and OB/GYN adoption. The company's stock closed at $2.67 on Monday, up to $2.81 in pre-market trading.
1 min readGilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readFemasys (FEMY) announced FDA approval of its modular PMA pathway for FemBloc, a non-surgical permanent birth control. The approach allows early review of key components. FemBloc is in the FINALE trial for U.S. approval. FEMY stock rose 35.45% in premarket trading.
2 min readFEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr
6 min readMifek Jeffrey Gerald (Chief Clinical-Medical Affairs) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readSipos Jeremy Alexander (Chief Technology Officer) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readCanning John Charles (Chief Operating Officer) purchased 4,375 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readElefant Dov (Chief Financial Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
2 min readLee-Sepsick Kathy (Chief Executive Officer) purchased 15,625 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.
1 min readFEMASYS INC (FEMY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Private Placement On August 7, 2026, Femasys Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agr
4 min read